Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1960 1
1964 1
1965 1
1968 1
1981 4
1982 4
1983 7
1984 9
1985 11
1986 11
1987 13
1988 13
1989 11
1990 14
1991 23
1992 25
1993 28
1994 32
1995 29
1996 30
1997 32
1998 25
1999 30
2000 29
2001 58
2002 57
2003 87
2004 114
2005 117
2006 154
2007 179
2008 179
2009 231
2010 260
2011 316
2012 412
2013 501
2014 572
2015 648
2016 658
2017 698
2018 768
2019 884
2020 1131
2021 1307
2022 601
Text availability
Article attribute
Article type
Publication date

Search Results

9,248 results
Results by year
Filters applied: . Clear all
Page 1
SARS-CoV-2 non-structural protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1.
Sun X, Liu Y, Huang Z, Xu W, Hu W, Yi L, Liu Z, Chan H, Zeng J, Liu X, Chen H, Yu J, Chan FKL, Ng SC, Wong SH, Wang MH, Gin T, Joynt GM, Hui DSC, Zou X, Shu Y, Cheng CHK, Fang S, Luo H, Lu J, Chan MTV, Zhang L, Wu WKK. Sun X, et al. Among authors: luo h. Cell Death Differ. 2022 Jan 8. doi: 10.1038/s41418-021-00916-7. Online ahead of print. Cell Death Differ. 2022. PMID: 34997207
Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.
Li Z, Peng M, Chen P, Liu C, Hu A, Zhang Y, Peng J, Liu J, Li Y, Li W, Zhu W, Guan D, Zhang Y, Chen H, Li J, Fan D, Huang K, Lin F, Zhang Z, Guo Z, Luo H, He X, Zhu Y, Li L, Huang B, Cai W, Gu L, Lu Y, Deng K, Yan L, Chen S. Li Z, et al. Among authors: luo h. Cell Metab. 2022 Mar 1;34(3):424-440.e7. doi: 10.1016/j.cmet.2022.01.008. Epub 2022 Feb 11. Cell Metab. 2022. PMID: 35150639 Free PMC article.
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
Yang W, Xing X, Yeung SJ, Wang S, Chen W, Bao Y, Wang F, Feng S, Peng F, Wang X, Chen S, He M, Zhang N, Wang H, Zeng B, Liu Z, Kidane B, Seder CW, Koyanagi K, Shargall Y, Luo H, Peng S, Cheng C. Yang W, et al. Among authors: luo h. J Immunother Cancer. 2022 Jan;10(1):e003497. doi: 10.1136/jitc-2021-003497. J Immunother Cancer. 2022. PMID: 35022193 Free PMC article.
Focal adhesion kinase inhibitors, a heavy punch to cancer.
Wu Y, Li N, Ye C, Jiang X, Luo H, Zhang B, Zhang Y, Zhang Q. Wu Y, et al. Among authors: luo h. Discov Oncol. 2021 Nov 22;12(1):52. doi: 10.1007/s12672-021-00449-y. Discov Oncol. 2021. PMID: 35201485 Free PMC article. Review.
Perspective of drug design with high-performance computing.
Li Z, Li H, Yu K, Luo HB. Li Z, et al. Among authors: luo hb. Natl Sci Rev. 2021 Jun 18;8(12):nwab105. doi: 10.1093/nsr/nwab105. eCollection 2021 Dec. Natl Sci Rev. 2021. PMID: 34992787 Free PMC article.
Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, Liu H, Cui T, Li N, Qiu W, Li G, Hou X, Luo H, Xue L, Zhang Y, Yue W, Liu Z, Wang X, Gao S, Pan Y, Galais MP, Zaanan A, Ma Z, Li H, Wang Y, Shen L; ORIENT-15 study group. Lu Z, et al. Among authors: luo h. BMJ. 2022 Apr 19;377:e068714. doi: 10.1136/bmj-2021-068714. BMJ. 2022. PMID: 35440464 Free PMC article. Clinical Trial.
9,248 results